Irbesartan/HCTZ Fixed Combinations in Patients of Different Racial/ethnic Groups with Uncontrolled Systolic Blood Pressure on Monotherapy

Overview

Journal J Natl Med Assoc

Publisher Elsevier

Specialty General Medicine

Date 2006 Apr 21

PMID 16623075

Citations 11

Authors

Elizabeth O Ofili

Keith C Ferdinand

Elijah Saunders

Joel M Neutel

George L Bakris

William C Cushman

James R Sowers

Michael A Weber

Affiliations

Soon will be listed here.

Abstract

The IrbesartaN/hydroChlorothiazide (HCTZ) bLood pressUre reductionS In diVErse patient populations (INCLUSIVE) trial was a multicenter, prospective, open-label, single-arm study evaluating the efficacy and safety of irbesartan/HCTZ fixed combinations in patients > or = 18 years old with uncontrolled systolic blood pressure (SBP, 140-159 mmHg; 130-159 mmHg for type-2 diabetes mellitus patients) after > or = 4 weeks of antihypertensive monotherapy. This analysis focused on different racial/ethnic subgroups. Treatment was sequential: placebo (4-5 weeks), HCTZ 12.5 mg (two weeks), irbesartan/HCTZ 150/12.5 mg (eight weeks) and irbesartan/HCTZ 300/25 mg (eight weeks). Overall, 515 Caucasians, 191 African Americans and 119 Hispanics/Latinos completing placebo treatment were enrolled. Mean SBP changes from baseline (placebo treatment end) to week 18 were -21.5 +/- 13.8 mmHg for Caucasians, -20.7 +/- 16.5 mmHg for African Americans and -22.9 +/- 13.2 mmHg for Hispanics/Latinos, respectively (p<0.001 for each). Mean diastolic BP (DBP) changes were statistically significant (p<0.001) and similar among racial/ethnic subgroups. By week 18, 70% (95% CI, 66%, 74%) of Caucasian, 66% (95% CI, 59%, 74%) of African-American and 65% (95% CI, 57%, 74%) of Hispanic/Latino patients achieved dual SBP/DBP goal. Treatments appeared to be well tolerated. In conclusion, irbesartan/HCTZ treatment provided SBP/DBP goal attainment in approximately two-thirds of Caucasian, African-American and Hispanic/Latino patients with SBP uncontrolled on antihypertensive monotherapy.

Citing Articles

Race, common genetic variation, and therapeutic response disparities in heart failure.

Taylor M, Sun A, Davis G, Fiuzat M, Liggett S, Bristow M JACC Heart Fail. 2014; 2(6):561-72.

PMID: 25443111 PMC: 4302116. DOI: 10.1016/j.jchf.2014.06.010.

Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy.

Neldam S, Zhu D, Schumacher H Int J Hypertens. 2013; 2013:627938.

PMID: 23844279 PMC: 3703394. DOI: 10.1155/2013/627938.

Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: planned analyses of a randomized trial.

Zhu D, Bays H, Gao P, Mattheus M, Voelker B, Ruilope L Integr Blood Press Control. 2013; 6:1-14.

PMID: 23637556 PMC: 3636767. DOI: 10.2147/IBPC.S33104.

Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.

Huang Q, Sheng C, Li Y, Ma G, Dai Q, Wang J Drugs R D. 2013; 13(2):109-17.

PMID: 23605903 PMC: 3689903. DOI: 10.1007/s40268-013-0013-9.

Aliskiren alone or in combination with hydrochlorothiazide in Hispanic/Latino patients with systolic blood pressure 160 mm Hg to <180 mm Hg (Aliskiren Alone or in Combination with Hydrochlorothiazide in Patients with Stage 2 Hypertension to Provide....

Black H, Aguirre P F, Wright M, Alessi T, Baschiera F J Clin Hypertens (Greenwich). 2012; 14(8):514-21.

PMID: 22863159 PMC: 8108917. DOI: 10.1111/j.1751-7176.2012.00672.x.

References

OBrien , Mee , ATKINS , Thomas . Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit. 1996; 1(1):55-61. View

ELLIOTT W . Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther. 1996; 60(5):582-8. DOI: 10.1016/S0009-9236(96)90155-1. View

Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12):851-60. DOI: 10.1056/NEJMoa011303. View

Silverstein R, Fenves A, Ram C . ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects. Postgrad Med. 2004; 116(2):31-8, 41. DOI: 10.3810/pgm.2004.08.1569. View

Neutel J, Saunders E, Bakris G, Cushman W, Ferdinand K, Ofili E . The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005; 7(10):578-86. PMC: 8109614. DOI: 10.1111/j.1524-6175.2004.04720.x. View

Rosenstock J, Rossi L, Lin C, MacNeil D, Osbakken M . The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther. 1999; 23(6):433-40. DOI: 10.1046/j.1365-2710.1998.00184.x. View

. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial. Heart Dis. 2001; 2(6):392-9. View

Brown N, Ray W, Snowden M, Griffin M . Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996; 60(1):8-13. DOI: 10.1016/S0009-9236(96)90161-7. View

Weir M, Smith D, Neutel J, Bedigian M . Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens. 2001; 14(7 Pt 1):665-71. DOI: 10.1016/s0895-7061(01)01296-1. View

10.

Wang Y, Wang Q . The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med. 2004; 164(19):2126-34. DOI: 10.1001/archinte.164.19.2126. View

11.

Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves R . Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1999; 12(8 Pt 1):797-805. DOI: 10.1016/s0895-7061(99)00053-9. View

12.

Richardson A, Piepho R . Effect of race on hypertension and antihypertensive therapy. Int J Clin Pharmacol Ther. 2000; 38(2):75-9. DOI: 10.5414/cpp38075. View

13.

Douglas J, Bakris G, Epstein M, Ferdinand K, Ferrario C, Flack J . Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163(5):525-41. DOI: 10.1001/archinte.163.5.525. View

14.

He J, Muntner P, Chen J, Roccella E, Streiffer R, Whelton P . Factors associated with hypertension control in the general population of the United States. Arch Intern Med. 2002; 162(9):1051-8. DOI: 10.1001/archinte.162.9.1051. View

15.

McGill J, Reilly P . Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol. 2001; 24(1):66-72. PMC: 6654963. DOI: 10.1002/clc.4960240111. View

16.

Flack J, Saunders E, Gradman A, Kraus W, Lester F, Pratt J . Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther. 2001; 23(8):1193-208. DOI: 10.1016/s0149-2918(01)80101-6. View

17.

Parving H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345(12):870-8. DOI: 10.1056/NEJMoa011489. View

18.

Toto R, Rinner S, Ram C . ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents?. Postgrad Med. 2004; 116(2):11-6, 19-22, 48. DOI: 10.3810/pgm.2004.08.1567. View

19.

. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23):2981-97. DOI: 10.1001/jama.288.23.2981. View

20.

Howe P, Phillips P, Saini R, Kassler-Taub K . The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens. 1999; 21(8):1373-96. DOI: 10.3109/10641969909070855. View